Other News To Note

• Cell Therapeutics Inc. (CTI), of Seattle, said the FDA granted orphan drug designation to Opaxio (paclitaxel poliglumex), formerly known as Xyotax, in glioblastoma multiforme (GBM) based on preliminary activity seen in Phase II results of Opaxio when added to standard therapy (temozolamide, or TMZ, plus radiation). The study showed encouraging progression-free and overall survival among patients with GBM, including those whose tumors expressed unmethylated MGMT.